1. CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center

2. CR-2 Historical Context: Therapeutic Advances in Advanced Pancreatic Cancer 1995: Gemcitabine presented to ODAC – Small but significant improvement in survival – Low objective response rate – Higher rates of Grade 3-4 myelosuppression,  LFTs, nausea and vomiting 1996: Gemcitabine approved by FDA for advanced pancreatic cancer

3. CR-3 Historical Context: Therapeutic Advances in Advanced Pancreatic Cancer 1996 – 2005 – 2 Phase III trials of new drug vs gemcitabine  None demonstrated a survival benefit – 8 Phase III trials of new drug + gemcitabine vs gemcitabine alone or with placebo  None demonstrated a survival benefit Clearly, improving outcomes in advanced pancreatic cancer has been more difficult than anticipated

4. CR-4 Tarceva and Advanced Cancers Pancreatic cancer is a fatal disease – Overall survival is the shortest of any solid tumor In other Phase III trials, the addition of a second agent to gemcitabine has added toxicity without an improvement in survival Tarceva was approved by the FDA in 2004 after demonstrating improvement in overall survival in patients with recurrent NSCLC Clinical experience and safety profile for Tarceva in greater than 18,000 patients

5. CR-5 The application under consideration today is a supplemental NDA, a mechanism created by the FDA to encourage sponsors to submit significant clinical trial data and thereby promote concordance between labeled indications and emerging clinical use of the drug. FDA Guidance for Industry: “If a product already has been shown to be safe and effective in the treatment of patients with a given type of cancer, a single, adequate and well- controlled, multicenter study demonstrating acceptable safety and effectiveness in another form of cancer that is known to have a generally similar pattern of responsiveness to chemotherapy may support labeling for that additional form of cancer.” † †FDA Guidance For Industry: FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products (December 1998) What is Under Consideration: sNDA

6. CR-6 NCIC CTG PA.3 is a Well-Designed, High- Quality Study Randomized, double-blind, placebo-controlled Phase III trial Conducted independently by a North American Cooperative Group with support from OSI Primary endpoint, improvement in overall survival achieved Therapeutic benefit conferred that is both statistically significant and clinically meaningful – 23% increase in overall survival – 30% increase in progression-free survival A point estimate, such as median survival, does not accurately capture this benefit

7. CR-7 NCIC CTG PA.3 is a Well-Designed, High- Quality Study Benefit associated with modest or infrequent toxicities – Primarily rash and diarrhea – Rare episodes of ILD-like events – No worsening of global quality of life Magnitude of toxicity is substantially less than what has been observed when other cytotoxic agents have been added to gemcitabine Tarceva is an oral, self-administered drug that does not place a burden on outpatient resource utilization or inconvenience the patient

8. CR-8 Implications of Study PA.3 for Patients with Advanced Pancreatic Cancer PA.3: the first trial in 10 years to demonstrate significant improvement in survival in patients with advanced pancreatic cancer The type and magnitude of benefits far outweigh the risk of toxicities Tarceva and gemcitabine: an important treatment option for patients and physicians who want a more aggressive, more effective treatment for advanced pancreatic cancer They should have that choice!